Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-01

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease.

The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by removing potentially damaging agents in a living organism, improves platelet function in patients with sickle cell disease (SCD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease

NCT01054768

Anemia, Sickle Cell

COMPLETED PHASE2

The Effect of Rivaroxaban in Sickle Cell Disease

NCT02072668

Sickle Cell Anemia Sickle Cell-Beta0-Thalassemia

COMPLETED PHASE2

Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease

NCT05675436

Sickle Cell Anemia Sickle Cell Thalassemia Sickle Cell Pain +5 more

ACTIVE_NOT_RECRUITING

Effects of HQK-1001 in Patients With Sickle Cell Disease

NCT01601340

Sickle Cell Disease Sickle Cell Anemia Sickle Cell Disorders +2 more

TERMINATED PHASE2

Topical Sodium Nitrite in Sickle Cell Disease and Leg Ulcers

NCT02863068

Sickle Cell Disease

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Antioxidant therapies targeted to specific enzymes or compartments may be beneficial in sickle cell anemia (SCA). MitoQ, the most extensively studied mitochondrial-targeted antioxidant, has been shown to be protective against ischemia/reperfusion injury in the heart, endothelial damage due to hypertension and ROS in animal models. MitoQ is commercially available as a dietary supplement to reduce overall oxidative stress and anti-ageing. However, MitoQ has not been tested either as a platelet antagonist or as an endothelial protectant in SCA patients. Investigators propose to conduct a small clinical trial of MitoQ in subjects with SCA to test the hypothesis that MitoQ scavenges platelet mtROS to prevent platelet activation and attenuate vascular dysfunction in SCA.

Investigators will test whether MitoQ decreases basal platelet activation in SCD patients and attenuates vascular dysfunction in subjects with SCA. Investigators will administer MitoQ orally to patients and healthy controls for 14 days. Investigators will obtain platelet count, hemolytic markers, platelet mtROS levels and activation markers, clinic BP measurements before and after MitoQ.

Adult male and female SCA subjects in steady state (n=10) and 5 healthy African-American volunteers will be recruited after obtaining informed consent.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sickle Cell Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Non randomized case control study design.

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sickle cell patients

Sickle Cell subjects administered oral MitoQ (20mg once a day for 14 days)

Group Type EXPERIMENTAL

MitoQ

Intervention Type DIETARY_SUPPLEMENT

Oral; 20mg once a day for 14 days

Non Sickle cell Control subjects

Normal control subjects administered oral MitoQ (20mg once a day for 14 days)

Group Type ACTIVE_COMPARATOR

MitoQ

Intervention Type DIETARY_SUPPLEMENT

Oral; 20mg once a day for 14 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MitoQ

Oral; 20mg once a day for 14 days

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects

* African American
* Patients with sickle cell anemia
* 18 years old or older

Control

* African American healthy controls
* 18 years of age or older

Exclusion Criteria

1. Pregnancy,
2. Known hypertension,
3. Hemodialysis and active obstructive sleep apnea requiring treatment.
4. Use of anti-platelet medication or have had transfusion in the 4 weeks prior to enrollment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes